PRISMAP Medical Radionuclides

Final delivery to users within PRISMAP – the European medical radionuclides programme

Nuclear Medicine uses radionuclides for imaging and therapeutic purposes. Over the past decade the theranostic approach has emerged, combining imaging and therapy to tailor treatment to the individual patient. Two products have received marketing authorisations in many countries, namely Luthatera® for neuroendocrine tumours and Pluvicto® for prostate cancer. Many other radiopharmaceuticals are being developed based on different vectors and radionuclides with different properties. These radionuclides are often difficult to access during the development and early stages of biomedical research.

This is the main objective of PRISMAP – The European medical radionuclides programme: to facilitate this development phase by providing access to novel, high-purity radionuclides for medical research. Over the past five years, PRISMAP has published five calls for user projects from which 47 projects out of the 67 submitted were selected. These projects were proposed by research teams from 19 different countries. 23 different radionuclides, more than three quarters of the portfolio proposed by PRISMAP, were requested, resulting in 159 deliveries for users.

In addition to providing radionuclides, PRISMAP also offered the possibility to conduct research projects at its five biomedical facilities for research teams requiring special equipment and/or authorisations. Our figure summarises all traffic related to the PRISMAP user projects. For projects carried out on the user's premises, the transport of radionuclides to the user is indicated, while for projects carried out at PRISMAP's biomedical facilities, the transport of radionuclides and the user's travel to the biomedical facilities are shown.



The last delivery to ICNAS (Portugal) took place on 19 November 2025. It was a shipment of astatine-211 for preclinical studies on glioblastoma. Astatine-211 belongs to the alpha emitters, a class of radionuclides that are particularly effective in destroying cancer cells.

The PRISMAP project – The European medical radionuclides programme, is ending on 31 December 2025. A follow-up project called PRISMAP+ has been submitted for funding in order to continue the work that has been started and to further strengthen our network over the next three years. This measure falls within the remit of the European Commission, which has committed itself to combating the social impact of cancer through Europe's Beating Cancer Plan, and in particular the SAMIRA Action Plan and the establishment of a European Radioisotope Valley Initiative.

Project website: https://www.prismap.eu/

Access platform: https://www.prismap.eu/radionuclides/

Funded projects: https://www.prismap.eu/access/user-projects/

Media kit: https://www.prismap.eu/mediakit/

Coordinator: Dr Thierry Stora, CERN: thierry.stora@cern.ch

Project management by SCIPROM: info@prismap.eu

Summary of user projects (Deliverable D1.3): https://zenodo.org/records/17898315

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP). This document reflects only the view of the author(s). The Agency is not responsible for any use that may be made of the information it contains.